



NDA 019684/S-033

## SUPPLEMENT APPROVAL

Pfizer Inc.  
Attention: Nataly Zarate  
Senior Manager, Pfizer Global Regulatory Affairs  
235 East 42nd Street  
New York, NY 10017-5755

Dear Nataly Zarate:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 14, 2021, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Procardia XL (nifedipine) extended-release tablets, 30 mg, 60 mg and 90 mg.

This “Changes Being Effectuated” supplemental new drug application provides the following labeling revisions to the drug product specification and to the full prescribing information in response to FDA’s supplement request letter dated March 25, 2021:

1. Description of the formulated overages for each strength
2. Revision to the drug product specification's acceptance criteria for Assay to (b) (4) % of target amount including overfill

### **APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information) with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Elizabeth Eydelman, MPH, Regulatory Business Process Manager, at (301) 796 - 5071.

Sincerely,

*{See appended electronic signature page}*

David Lewis, PhD  
Branch Chief, Branch 2  
Division of Post-Marketing Activities I  
Office of Lifecycle Drug Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure:

Content of Labeling



David  
Lewis

Digitally signed by David Lewis  
Date: 11/09/2021 08:51:32AM  
GUID: 508da72000029f287fa31e664741b577